Medisolar (Co-CEOs Seungyeon Lee and Donggu Lee) , a customized food care solution company, announced on the 3rd that it has successfully completed a total investment of 13 billion won. Premier Partners, Samsung Venture Investment, and Red Badge Pacific participated as major investors in this investment, and highly evaluated Medisolar’s technological prowess and growth potential.
Medisola is a food tech company that was planned and established in December 2021 by CEO Seungyeon Lee, who was formerly the Vice President of Etsfoods and led the overall establishment, marketing, sales, and operation of retail brands such as John Cook Deli Meat, and CEO Donggu Lee, who led investments in the healthcare and bio fields at KB Investment. Last year, it attracted about 2 billion won in investment through a pre-A round.
Medisol implements home-based food care that encompasses the care food area that starts when you are healthy, and the medical food area that provides intensive care when you are concerned about your health, and provides sustainable health management solutions through food.
In addition to simply providing a healthy diet, the company is expanding into the digital healthcare sector through its own AI-based healthcare platform, 'ArchenX', which it is developing, to advance diet design algorithms, discover data-based food materials, and develop digital diet prescription technology.
In particular, through joint clinical intervention research with Severance Hospital that has been ongoing for over 6 years, we are verifying clinical effects on actual patients, and securing both technical reliability and academic achievements. These studies are based on various target groups such as breast cancer relapse patients, hyperlipidemia, and chronic kidney disease, leading to SCI(E)-level papers, and are establishing a high entry barrier compared to competitors in the medical verification-based dietary intervention market.
Through this investment attraction, Medisol plans to accelerate its all-round business expansion, including ▲enhancing its AI-based diet design algorithm, ▲expanding research and development of disease-tailored functional foods, ▲expanding its health data-based food care platform, and ▲accelerating its entry into the B2B and B2C markets.
Co-CEO Seungyeon Lee, who experienced severe malnutrition in the past and began researching the Korean Mediterranean diet with medical professionals and professional clinical nutritionists, said, “The innovation of dietary life centered on disease prevention and management based on home nutrition is now an inevitable trend,” and “We will present a future in which everyone is nutritionally equal, based on the nutrition that Koreans absolutely need.” Co-CEO Donggu Lee also emphasized, “Medisola implements the philosophy of ‘Food is Medicine’ based on personal health information and nutritional data, and aims to transform food into a new form of treatment,” and “Through this investment, we will leap forward as a global company leading the customized food care industry.”
Samsung Venture Investment, which led this investment, said, “Medisola is a company that has realized a sophisticated fusion of technology, data, and medicine, and is attracting attention as a next-generation healthcare solution company that blurs the boundaries between food and medicine,” adding, “We expect to see continued market expansion through platform business and functional food development.”
Medisol plans to contribute to disease prevention and quality of life improvement through science-based food care solutions that combine medicine, nutrition, and IT, as well as to enter the global market and expand strategic partnerships.
- See more related articles
You must be logged in to post a comment.